These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34038463)

  • 1. Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
    Cheng CN; Huang SY; Lien PW; Huang ST; Lin FJ
    PLoS One; 2021; 16(5):e0252124. PubMed ID: 34038463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.
    Zamagni E; Dhanasiri S; Ghale A; Moore A; Roussel M
    Leuk Lymphoma; 2021 Oct; 62(10):2492-2501. PubMed ID: 34121589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
    Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
    Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
    Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
    Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
    PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
    Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M
    Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
    Liu Y; Tang CH; Qiu H; Siggins S; Hou HA
    Sci Rep; 2021 Jan; 11(1):1112. PubMed ID: 33441901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
    Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
    Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
    Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
    Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
    Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
    J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
    Chan H; Chai K; Shih S; Lewsey R; Chen K; McDiarmid B; Jackson S; Simpson D
    Br J Haematol; 2019 Nov; 187(4):470-477. PubMed ID: 31298750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
    Ramasamy K; Dhanasiri S; Thom H; Buchanan V; Robinson S; D'Souza VK; Weisel K
    Leuk Lymphoma; 2020 Mar; 61(3):668-679. PubMed ID: 31709875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 18. Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden.
    Nahi H; Walinder G; Patel V; Qu Y; Levine A; Majer I; Kutikova L; Hellqvist Franck E; Svensson MK; Hansson M
    Acta Haematol; 2021; 144(5):519-527. PubMed ID: 33631745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
    Qin XQ; An G; Li ZJ; Liu LT; Xu Y; Yang LH; Ma YP; Deng SH; Sui WW; Qin Y; Feng XY; Zang MR; Yang WJ; Zhang YR; Yi SH; Wang TY; Lv R; Zou DH; Zhao YZ; Qiu LG
    Blood Adv; 2019 Mar; 3(5):751-760. PubMed ID: 30833275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.